JEFFREY M. JONAS - 03 Feb 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
/s/ Anne Marie Cook, as Attorney-in-Fact for Jeffrey M. Jonas
Issuer symbol
SAGE
Transactions as of
03 Feb 2023
Net transactions value
-$63,016
Form type
4
Filing time
07 Feb 2023, 15:11:19 UTC
Previous filing
05 Jan 2023
Next filing
10 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +5,100 +4.3% $0.000000 123,408 03 Feb 2023 Direct F1
transaction SAGE Common Stock Tax liability $63,016 -1,427 -1.2% $44.16 121,981 03 Feb 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 10, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 17,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 5,100 shares.